NewsRx

Search our medical news database

HIV/AIDS Research

Autologous p2gag peptide blocks HIV-1 virion autolysis

Published in AIDS Weekly, June 7th, 2004

Autologous p2gag peptide blocks HIV-1 virion autolysis.

"Our previous study suggested that the p2gag peptide, AEAMSQVTNTIM, inhibits human immunodeficiency virus type 1 (HIV-1) protease (PR) activity in vitro," wrote researchers in Japan. "In this study, Ala substitutions (Met4Ala and Thr8Ala) and deletion of amino acid Asn9 within the nona p2gag peptide (AEAMSQVTN) were found to decrease the inhibitory effect on HIV-1 PR activity.

"Furthermore, treatment of PMA-activated latently infected T lymphocytes, ACH-2 cells, with the p2gag peptide (100 and 250 PM) resulted in a decrease...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook